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Objectives The goal of this study was to examine the prospective association between oxidation-specific biomarkers, pri-
marily oxidized phospholipids (OxPL) on apolipoprotein B-100–containing lipoproteins (OxPL/apoB) and lipoprotein
(a) [Lp(a)], and risk of peripheral artery disease (PAD). We examined, as secondary analyses, indirect measures
of oxidized lipoproteins, including autoantibodies to malondialdehyde-modified low-density lipoprotein (MDA-LDL)
and apolipoprotein B-100 immune complexes (ApoB-IC).
Background Biomarkers to predict the development of PAD are lacking. OxPL circulate in plasma, are transported by Lp(a),
and deposit in the vascular wall and induce local inflammation.
Methods The study population included 2 parallel nested case-control studies of 143 men within the Health Professionals
Follow-up Study (1994 to 2008) and 144 women within the Nurses’ Health Study (1990 to 2010) with incident
confirmed cases of clinically significant PAD, matched 1:3 to control subjects.
Results Levels of OxPL/apoB were positively associated with risk of PAD in men and women: pooled relative risk: 1.37,
95% confidence interval: 1.19 to 1.58 for each 1-SD increase after adjusting age, smoking, fasting status,
month of blood draw, lipids, body mass index, and other cardiovascular disease risk factors. Lp(a) was similarly
associated with risk of PAD (pooled adjusted relative risk: 1.36; 95% confidence interval: 1.18 to 1.57 for each
1-SD increase). Autoantibodies to MDA-LDL and ApoB-IC were not consistently associated with risk of PAD.
Conclusions OxPL/apoB were positively associated with risk of PAD in men and women. The major lipoprotein carrier of
OxPL, Lp(a), was also associated with risk of PAD, reinforcing the key role of OxPL in the pathophysiology of ath-
erosclerosis mediated by Lp(a). (J Am Coll Cardiol 2013;61:2169–79) © 2013 by the American College of Car-
diology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.02.047Approximately 10 million U.S. adults have peripheral artery
disease (PAD), including 23% of those 70 years of age or
older (1,2). Peripheral artery disease is associated with
substantial morbidity, cost (3), and functional decline (4)
and might require limb amputation in extreme cases. De-
spite its high prevalence and associated morbidity, risk
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Evidence from cellular and animal experiments suggests
that oxidative stress plays a key, modifiable role in the
etiology of atherosclerosis (5,6). However, there is a lack of
appropriate epidemiological markers to measure oxidation:
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Oxidation Biomarkers and Peripheral Artery Disease May 28, 2013:2169–79many biomarkers lack the neces-
sary combination of reliability, ac-
curacy, cost-effectiveness, and ease
of measurement; and few have
been examined specifically with re-
spect to PAD. Oxidized phospho-
lipids (OxPL), a marker of lipid
oxidation transported by lipopro-
tein (a) [Lp(a)] in plasma (7,8),
might provide insight into the role
of oxidative stress in atherosclero-
sis. Pro-inflammatory OxPL on
Lp(a) and other apoB-100 –
containing lipoproteins upregulate
proinflammatory genes and proin-
flammatory responses of several
arterial wall cells and initiate a
localized inflammatory cascade
(9,10).
These oxidation-specific epi-
topes—such as OxPL and malon-
dialdehyde (MDA) epitopes—
represent danger-associated mo-
lecular patterns that are detrimental
to the host; are present on apo-
ptotic cells, oxidized low-density
lipoprotein (LDL), and lipids;
and often share molecular iden-
tity/mimicry with epitopes on
pathogens (11). In response to
uch danger-associated molecular patterns, macrophage
cavenger receptors, immune effector proteins such as auto-
ntibodies to malondialdehyde-modified low-density lipo-
rotein (MDA-LDL), complement factor H (12), and
-reactive protein have been selected and expanded to bind
nd neutralize their pro-inflammatory effects.
Oxidized phospholipids on apolipoprotein B-100 –
ontaining lipoproteins (OxPL/apoB) have been associated
ith carotid and femoral atherosclerosis measured by ultra-
ound (13), myocardial infarction (MI), stroke, revascular-
zation, and total mortality in selected, largely clinical
opulations (7). Immunoglobulin (Ig) M autoantibodies to
DA-LDL have also been inversely associated with
ltrasound-detected carotid and femoral atherosclerosis
14,15); and in another small cross-sectional study, autoan-
ibody titers against oxidized LDL were increased in pa-
ients with early onset PAD (16). However, no adequately
owered prospective cohort studies have examined the
ssociation between oxidation-specific biomarkers and risk
f incident clinically manifested PAD in healthy popula-
ions. The goal of this study was to examine the prospective
ssociation between oxidation-specific biomarkers, primar-
ly oxidized phospholipids (OxPL) on apolipoprotein B-
00–containing lipoproteins (OxPL/apoB) and lipoprotein (a)
Lp(a)], and risk of peripheral artery disease (PAD). We
Abbreviations
and Acronyms
ABI  ankle-brachial index
ApoB  apolipoprotein
B-100–containing
lipoproteins
ApoB-IC  apoB-immune
complexes
BMI  body mass index
BSA  bovine serum
albumin
CI  confidence interval
CVD  cardiovascular
disease
Ig  immunoglobulin
LDL  low-density
lipoprotein
Lp(a)  lipoprotein (a)
MDA  malondialdehyde
MI  myocardial infarction
OxPL  oxidized
phospholipids
PAD  peripheral artery
disease
PC  phosphocholine
RLU  relative light units
RR  incidence rate ratio/
relative riskxamined, as secondary analyses, indirect measures of oxidized tipoproteins, including autoantibodies to malondialdehyde-
odified low-density lipoprotein (MDA-LDL) and apolipo-
rotein B-100 immune complexes (ApoB-IC).
ethods
tudy population. The HPFS (Health Professionals
ollow-up Study) is a prospective cohort study of 51,529
ale dentists, optometrists, pharmacists, podiatrists, osteo-
athic physicians, and veterinarians 40 to 75 years of age
hat began in 1986. The NHS study (Nurses’ Health Study)
s a prospective cohort study of 121,700 female nurses 30 to
5 years of age that began in 1976. From individuals in
hese 2 studies, 18,224 men provided blood specimens in
994, and 32,826 women provided a blood sample in 1989.
e excluded individuals who had a history of cardiovascular
isease (CVD)—including MI; surgical/percutaneous re-
ascularization of the coronary, carotid, or peripheral beds;
onfirmed PAD; stroke; and transient ischemic attack.
The case-control analytic datasets include 143 incident
ases and 429 control subjects in the HPFS study and 144
ncident cases and 432 control subjects in the NHS study.
ases were matched 1:3 to control subjects on age, race
NHS study only), month of blood draw (within 3 months),
asting status, and smoking history (never/former/current).
e selected control subjects at random, conditional on the
atching factors, from participants free of PAD at the time
he case occurred (risk set sampling). Because older age
ategories had fewer participants, we relaxed the age match
ange year-by-year if necessary to a maximum of within 3
ears. The Harvard School of Public Health Human Sub-
ects Committee approved both studies.
ssessment of OxPL, Lp(a), autoantibodies, and immune
omplexes. Blood samples were shipped overnight with a
old pack to the central laboratory, centrifuged on arrival,
liquotted, and stored in liquid nitrogen at 130°C to
196°C. The HPFS specimens were anticoagulated with
thylenediaminetetraacetic acid, and NHS specimens were
nticoagulated with heparin, and 95% of HPFS bloods and
7% of NHS bloods were received within 24 h. A validated
lasma assay was used to measure OxPL/apoB, with the
urine monoclonal antibody E06 that recognizes the phos-
hocholine (PC) group on oxidized but not on native
hospholipids (reviewed in detail in Taleb et al. [7] and
eferences therein). E06 similarly recognizes the PC cova-
ently bound to bovine serum albumin (BSA), as in
C-BSA. A 1:50 dilution of plasma in phosphate-buffered
aline is added to microtiter wells coated with monoclonal
ntibody MB47, which binds a saturating amount of apoB-
00 to each well. Finally, biotinylated E06 is used to
etermine OxPL/apoB in relative light units (RLU).
ithin-person 5-year reproducibility of frozen samples is
igh (r  0.78) (13), and pilot-tests showed that OxPL/
poB levels are stable over 24 h on ice (intra-class correla-
ion coefficient  0.96).
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May 28, 2013:2169–79 Oxidation Biomarkers and Peripheral Artery DiseaseTo facilitate comparison of absolute OxPL/apoB levels
across studies, we also describe the reporting of OxPL/apoB
levels as nanomolar (nmol/l or nM) OxPL rather than RLU
OxPL with a novel standard curve of PC equivalents. The
standard curve is generated by plating known concentrations
of phosphocholine-modified bovine serum albumin
(PC-BSA), which has approximately 16 mole of PC/mole
of BSA (Biotech Technologies, Novato, California), and is
recognized by E06. Biotin-E06 is then added to detect the
number of moles of PC in the linear range on the plate and
is measured in RLU. This standard curve is then used to
convert the RLU derived from wells containing individual
human samples to OxPL equivalents. This new method is
reported as nanomoles of PC found on OxPL/l plasma (i.e.,
nanomolar or nM) for each sample. Because each mole of
OxPL has 1 PC headgroup recognized by E06, this can be
reported as nM OxPL.
The Lp(a) levels were determined with a chemilumines-
cent enzyme-linked immunoadsorbent assay with MB47-
coated wells, a 1:400 plasma dilution, and biotinylated
monoclonal antibody LPA4, as described previously (17).
Chemiluminescent enzyme-linked immunoadsorbent assay
was used to measure IgG and IgM autoantibodies to
MDA-LDL and apoB-immune complexes (ApoB-IC), as
previously described (18). Measured coefficients of variation
in duplicate samples were 8% for OxPL/apoB, 13% for
Lp(a), 11% for IgG autoantibodies, 9% for IgM autoanti-
bodies, 10% for IgG ApoB-IC, and 10% for IgM ApoB-IC
in the HPFS study. Coefficients of variation were 21% for
OxPL/apoB, 13% for Lp(a), 9% for IgG autoantibodies, 7%
for IgM autoantibodies, 16% for IgG ApoB-IC, and 25%
for IgM ApoB-IC in the NHS study.
Assessment of PAD. Participants reported the occurrence
f professionally diagnosed medical conditions, including
laudication and revascularization for arterial disease of the
eg, during the previous 2 years on biennial mailed ques-
ionnaires. We collected medical records from treating
hysicians and hospitals for those who reported either
ondition. Professionals blinded to biomarker status re-
iewed and confirmed PAD diagnoses with medical records.
We defined PAD as arterial disease below the aortic
ifurcation (i.e., excluding abdominal aortic aneurysm and
enal artery stenosis) as described previously (19). Con-
firmed PAD required at least 1 of the following (in order of
severity/certainty): 1) report of amputation, bypass, or other
revascularization procedure (e.g., angioplasty) for occlusive
artery disease; 2) angiogram showing at least 50% stenosis of
at least 1 artery with congruent symptoms in the ipsilateral
limb; 3) ankle-brachial index (ABI)0.9; or 4) diagnosis of
physician confirmed by medical record review.
Assessment of covariates. Questionnaires provided infor-
mation about medical history and lifestyle habits, including
detailed information about smoking, medication use,
weight, parental history of MI, alcohol, physical activity,
diet, and post-menopausal hormone use. Participants re-
ported the average amount of time they spent/week onvarious activities such as walking, jogging, running, bicy-
cling, and tennis. This information was used to calculate
weekly energy expenditure in metabolic equivalent task-
hours. We calculated body mass index (BMI) by dividing
weight (kg) by squared height (m2). Both physical activity
nd BMI measures are highly valid (20–22).
A laboratory certified by the National Heart, Lung and
lood Institute/Centers for Disease Control and Prevention
ipid Standardization Program analyzed all other biochem-
cal markers by means of commercially available analytic
ystems. The laboratory measured high-density lipoprotein
holesterol and triglycerides enzymatically and LDL cho-
esterol by a homogenous direct method from Roche Diag-
ostics (Indianapolis, Indiana). An immunoturbidimetric
ssay on the Roche P Modular system from Roche Diag-
ostics quantified the concentration of high-sensitivity
-reactive protein, with reagents and calibrators from
iaSorin (Stillwater, Minnesota). The Roche P Modular
ystem uses turbidimetric immunoinhibition and hemolyzed
hole blood or packed red cells to determine hemoglobin
1c (Roche Diagnostics, Indianapolis, Indiana).
Statistical analysis. We used generalized linear mixed
models and Cochran-Mantel-Haenszel tests to compare
continuous variables and categorical variables by case/
control status, respectively, accounting for clustering by
matching status. We examined the shape of the associations
of OxPL/apoB, Lp(a), autoantibodies, and ApoB-IC with
PAD risk with cubic splines, adjusting for all covariates. We
used conditional logistic regression, conditioning on match-
ing factors, to estimate odds ratios for PAD according to
level of OxPL/apoB and present estimates adjusted for
matching factors and additionally for other PAD risk
factors. Because we employed risk set sampling, we report
these odds ratios as unbiased estimates of the incidence rate
ratio (RR).
We included covariates in our models as linear vari-
ables if appropriate or as categorical variables if discrete
or their association with PAD was nonlinear. We
checked for multicollinearity among covariates with vari-
ance inflation factors. Because the test for heterogeneity
was not statistically significant, we used meta-analysis
with fixed effects to pool our RR estimates for OxPL/
apoB and Lp(a). We tested effect modification by includ-
ing interaction terms between OxPL/apoB and the po-
tential effect modifier (continuous variable) in our models
and pooled the interaction terms for men and women
with a meta-analysis with fixed effects. We analyzed
levels of autoantibodies and ApoB-IC in similar fashion.
All analyses used SAS statistical software (version 9.2,
Cary, North Carolina).
Results
Among men, medical reports of amputation, bypass, or
other revascularization procedure confirmed 87 PAD cases
(61%), angiogram or Doppler ultrasound confirmed 15 cases
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Oxidation Biomarkers and Peripheral Artery Disease May 28, 2013:2169–79(10%), ABI 0.9 confirmed 23 cases (16%), and physician
iagnosis confirmed 18 cases (13%). Among women, sur-
ery or procedure confirmed 74 cases (51%), angiogram
onfirmed 24 cases (17%), ABI confirmed 39 cases (27%),
nd physician diagnosis confirmed 7 cases (5%). Compared
ith control subjects, PAD cases had higher levels of
Baseline Characteristics of Cases and Matched Control SubjectsTable 1 Baseline Characteristics of Cases and Matched Contro
Women
Cases Control
(n  144) (n 
Age (yrs) 59.9 5.2 60.0
Oxidation-related factors
OxPL/apoB (nM) 8.46 (3.9–19.3) 5.00 (2.9–
OxPL/apoB (RLU) 4,882 (2,237–11,135) 2,887 (1,64
Lipoprotein (a) (mg/dl) 35.1 (8.7–72.3) 13.1 (4.9–
IgG AA to MDA-LDL (RLU) 8,776 (6,394–12,669) 8,541 (5,57
IgM AA to MDA-LDL (RLU) 20,457 (14,001–26,529) 18,866 (13,9
IgG ApoB-IC (RLU) 1,106 (862–1,439) 1,076 (791
IgM ApoB-IC (RLU) 1,490 (897–2,574) 1,478 (960
Lipids
Triglycerides (mg/dl) 110 (85–161) 106 (73–
HDL-C (mg/dl) 60.5 19.9 62.1
LDL-C (mg/dl) 148 44 142
hsCRP (mg/l) 2.56 (1.25–4.70) 1.62 (0.73
HbA1c (%) 5.46 (5.28–5.72) 5.33 (5.16
Smoking status
Never 30 (21%) 90 (21%
Past 56 (39%) 170 (39%
Current 58 (40%) 172 (40%
1–14 cigarettes/day 18 (13%) 86 (20%
15–34 cigarettes/day 31 (22%) 80 (19%
35 cigarettes/day 9 (6%) 5 (1%)
Pack-yrs (yrs) 32.3 25.6 22.0
Physical activity (MET h/wk) 12.8 (4.7–24.9) 13.6 (5.0–
History of hypertension 68 (47%) 137 (32%
History of diabetes 19 (13%) 12 (3%)
History of hypercholesterolemia 84 (58%) 200 (46%
Alcohol
Never drinker 49 (34%) 130 (30%
Former drinker 44 (31%) 137 (32%
1 drink/day 29 (20%) 109 (25%
1–1.9 drinks/day 12 (8%) 20 (5%)
2 drinks/day 9 (6%) 31 (7%)
Parental history of MI age 60 yrs 31 (22%) 61 (14%
BMI category
25 84 (58%) 259 (60%
25–29.9 38 (26%) 132 (31%
30 22 (15%) 41 (9%)
Aspirin use 29 (20%) 89 (21%
Post-menopausal 131 (95%) 390 (95%
Ever used post-menopausal hormones† 96 (72%) 257 (63%
Currently using post-menopausal
hormones
57 (43%) 183 (45%
Values are mean  SD, median (interquartile range), or n (%). *Generalized linear mixed mode
matching/correlation between control subjects); matching criteria were age, month of blood draw
AA to MDA-LDL autoantibodies to malondialdehyde-modified low-density lipoprotein cholester
-reactive protein; HbA1c  hemoglobin A1c; HDL-C  high-density lipoprotein cholesterol; Ig  i
I  myocardial infarction; OxPL/apoB  oxidized phospholipids on apolipoprotein B-100–contaraditional CVD risk factors (Table 1). Although cases andcontrol subjects were matched on current smoking status,
cases still had a significantly higher average number of
pack-years compared with control subjects.
OxPL/apoB and Lp(a). Women had considerably lower
levels of OxPL/apoB compared with men, whereas the
distribution of Lp(a) overlapped substantially across sexes,
jects
Men
ts Cases Control Subjects
p Value* (n  143) (n  429) p Value*
Matched 65.4 8.1 65.3 8.1 Matched
0.001 15.24 (12.4–23.6) 14.15 (12.3–19.4) 0.02
32) 0.001 8,800 (7,162–1,3601) 8,173 (7,126–11,184) 0.02
0.001 7.6 (2.8–34.3) 4.5 (1.6–17.7) 0.007
758) 0.34 2,313 (1,411–4,949) 2,733 (1,741–4,350) 0.36
,145) 0.22 9,684 (5,836–14,986) 9,213 (6,363–13,823) 0.16
) 0.94 1,620 (1,265–2,243) 1748 (1,376–2,374) 0.22
) 0.17 885 (562–1,600) 921 (601–1,425) 0.29
0.34 143 (105–195) 115 (80–165) 0.001
0.42 41.7 11 48.5 14 0.001
0.16 139 35 131 33 0.02
) 0.07 2.24 (1.2–3.5) 1.18 (0.5–2.3) 0.005
) 0.001 5.56 (5.3–6.0) 5.41 (5.2–5.6) 0.001
Matched 23 (18%) 82 (20%) Matched
Matched 78 (60%) 242 (59%) Matched
Matched 32 (22%) 90 (21%) Matched
15 (11%) 44 (11%)
11 (8%) 33 (8%)
4 (3%) 9 (2%)
0.001 28.7 24 22.5 22 0.001
0.69 22.7 (8.0–43.8) 27.4 (10.3–52.8) 0.003
0.001 70 (49%) 130 (30%) 0.001
0.001 28 (20%) 16 (4%) 0.001
0.01 82 (57%) 187 (44%) 0.005
35 (24%) 84 (20%)
24 (17%) 80 (19%)
0.43 39 (27%) 123 (29%) 0.81
23 (16%) 65 (15%)
22 (15%) 76 (18%)
0.03 22 (15%) 44 (10%) 0.09
62 (43%) 204 (48%)
0.13 67 (47%) 196 (46%) 0.42
14 (10%) 29 (7%)
0.91 80 (56%) 184 (43%) 0.01
0.72
0.04
0.84
ontinuous variables and Cochran-Mantel-Haenszel test for categorical variables (to account for
g status, and smoking status. †Among post-menopausal women.
-IC apolipoprotein B-100 immune complexes; BMI body mass index; hsCRP high-sensitivity
globulin; LDL-C  low-density lipoprotein cholesterol; MET h  metabolic equivalent task-hours;
oproteins; RLU  relative light units.l Sub
Subjec
432)
5.2
10.6)
9–6,1
43.1)
2–12,
03–25
–1,494
–2,393
145)
17.1
38
–3.33
–5.55
)
)
)
)
)
21.3
28.1)
)
)
)
)
)
)
)
)
)
)
)
)
ls for c
, fastin
ol; ApoBwith somewhat greater levels among women. OxPL/apoB
t
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May 28, 2013:2169–79 Oxidation Biomarkers and Peripheral Artery Diseasewas not strongly correlated with standard CVD risk factors
(Online Table 1).
The association between OxPL/apoB and Lp(a) and risk
of PAD appeared linear (Figs. 1 to 3), and likelihood ratio
ests for nonlinearity were not statistically significant
p  0.05), comparing a model with the linear term with a
odel with the linear and cubic spline terms. Therefore we
iscuss our results with units of 1 SD of nM OxPL/apoB.
e have additionally presented our results with RLU,
ecause all previous work used OxPL/apoB measured in
LU. There was a 51% (95% confidence interval [CI]: 24%
o 85%) increase in risk of PAD for each 1-SD increase in
xPL/apoB in women and a 23% (95% CI: 0% to 52%)
Figure 1 Adjusted Relationship Between Plasma Levels of OxP
Data derive from a cubic spline conditional logistic regression model with age, rac
ing variables. The model is adjusted for triglycerides, high-density lipoprotein chole
bin A1c, history of diabetes, history of hypertension, pack-years of smoking, paren
physical activity, post-menopausal hormone use (women only), and sex (pooled on
protein B-100–containing lipoproteins; OxPL  oxidized phospholipids; PAD  per
Figure 2 Adjusted Relationship Between Plasma Levels of Lp(a
Lp(a)  lipoprotein (a); other abbreviations as in Figure 1.increase in men in full multivariable models (Table 2).
These estimates were essentially the same for matching-
adjusted models (53% in women, and 24% in men). Simi-
larly, there was a 52% (95% CI: 24% to 87%) increase in risk
of PAD for each 1-SD increase in Lp(a) in women, and a
24% (95% CI: 0% to 53%) increase in men in full
multivariable models (Table 3).
Because we did not observe statistically significant heter-
ogeneity between the NHS and HPFS studies, we pooled
our results for OxPL/apoB and Lp(a) in women and men
(Tables 2 and 3). In pooled analyses, a 1-SD increase in
OxPL/apoB was associated with a 37% (95% CI: 19% to
58%) increased risk of PAD, adjusting for all covariates. A
oB and RR of PAD
en only), smoking status, fasting status, and date of blood sampling as match-
, low-density lipoprotein cholesterol, high-sensitivity C-reactive protein, hemoglo-
ory of myocardial infarction before age 60, aspirin use, body mass index,
e 95% confidence interval (CI) is indicated by the dashed lines. ApoB  apolipo-
l artery disease; RR  relative risk.
RR of PADL/ap
e (wom
sterol
tal hist
ly). Th
iphera) and
o2174 Bertoia et al. JACC Vol. 61, No. 21, 2013
Oxidation Biomarkers and Peripheral Artery Disease May 28, 2013:2169–791-SD increase in Lp(a) was associated with almost the same
magnitude of increased risk of PAD. With tertiles to
categorize OxPL/apoB and Lp(a), men and women in the
highest compared with lowest tertile of both biomarkers had
approximately double the risk of PAD. In additional anal-
yses, we found no interactions of OxPL/apoB with age,
years of follow-up, LDL cholesterol, autoantibodies to
MDA-LDL, or ApoB-IC.
Figure 3 Adjusted Relationship Between Plasma Levels of OxP
RLU  relative light units; other abbreviations as in Figure 1.
Relative Risks and 95% CIs for Peripheral Artery Disease AccordinTable 2 Relative Risks and 95% CIs for Peripheral Artery Disea
W
Per 1-SD
Increase
(7.17)
Tertile
1 2 3
Range
(nM)
0.00–3.72 3.73–9.55 9.56–46.09
Cases 144 33 43 68
Model 1 1.53 (1.30–1.79) 1.0 (ref) 1.44 (0.86–2.41) 2.73 (1.67–4.4
Model 2 1.50 (1.26–1.79) 1.0 (ref) 1.58 (0.91–2.75) 2.92 (1.71–5.0
Model 3 1.51 (1.24–1.85) 1.0 (ref) 1.38 (0.75–2.54) 2.55 (1.41–4.6
Per 1-SD
Increase
(10.38)
Tertile
1 2 3
Range
(nM)
7.85–12.93 12.94–16.85 16.86–82.75
Cases 143 41 47 55
Model 1 1.24 (1.05–1.46) 1.0 (ref) 1.15 (0.70–1.87) 1.50 (0.92–2.4
Model 2 1.31 (1.09–1.58) 1.0 (ref) 1.23 (0.72–2.08) 1.78 (1.03–3.0
Model 3 1.23 (1.00–1.52) 1.0 (ref) 1.03 (0.57–1.86) 1.50 (0.81–2.7
P
Model 3 1.37 (1.19–1.58) 1.0 (ref) 1.18 (0.77–1.82) 1.97 (1.28–3.0
Values are relative risk (95% CI) unless otherwise indicated. Model 1: adjusted for matching fact
matching factors, triglycerides, HDL-C, LDL-C, hsCRP, and HbA1c. Model 3: adjusted for matching fa
f smoking, physical activity, hypertension, diabetes, hypercholesterolemia, BMI, aspirin use, and post-m
CI  confidence interval; other abbreviations as in Table 1.IgG and IgM autoantibodies and immune complexes.
We did not find consistent associations of autoantibodies to
MDA-LDL with risk of PAD. The relative risks fluctuated
across tertiles and the CIs were consistent with a broad
range of risk estimates (Table 4), although it was of interest
that there was a significant inverse relationship of IgG to
MDA-LDL in men but not women. The IgG and IgM
ApoB-IC were not statistically significantly associated with
oB (RLU) and RR of PAD
evel of OxPL/ApoBccording to Level of OxPL/ApoB
Per 1-SD
Increase
(4,142)
Tertile
1 2 3
ange
(RLU)
0–2,150 2,151–5,517 5,518–26,622
ases 144 33 43 68
odel 1 1.53 (1.30–1.79) 1.0 (ref) 1.44 (0.86–2.41) 2.73 (1.67–4.48)
odel 2 1.50 (1.26–1.79) 1.0 (ref) 1.58 (0.91–2.75) 2.92 (1.71–5.00)
odel 3 1.51 (1.24–1.85) 1.0 (ref) 1.38 (0.75–2.54) 2.55 (1.41–4.64)
Per 1-SD
Increase
(5,999)
Tertile
1 2 3
ange
(RLU)
4,535–
7,518
7,519–9,730 9,731–47,792
ases 143 42 46 55
odel 1 1.24 (1.05–1.46) 1.0 (ref) 1.09 (0.67–1.78) 1.46 (0.90–2.38)
odel 2 1.31 (1.09–1.58) 1.0 (ref) 1.15 (0.68–1.96) 1.72 (0.99–2.97)
odel 3 1.23 (1.00–1.52) 1.0 (ref) 0.99 (0.55–1.79) 1.46 (0.79–2.70)
odel 3 1.37 (1.18–1.58) 1.0 (ref) 1.17 (0.76–1.80) 1.95 (1.27–3.00)
e, race [women only], month of blood draw, fasting status, and smoking). Model 2: adjusted for
riglycerides, HDL-C, LDL-C, hsCRP, HbA1c, parental history of MI before 60 years of age, pack-yearsL/apg to Lse A
omen
R
C
8) M
0) M
4) M
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variables or in tertiles (Table 5).
OxPL/apoB and Lp(a) in context. In women, the
C-statistic value for area under the receiver-operating
characteristic curve increased from 0.725 to 0.756 and
Relative Risks and 95% CIs for Peripheral ArterTable 3 Relative Risks and 95% CIs for Per
W
Per 1-SD
Increase (28.8)
Range (mg/dl) 0.
Cases 144
Model 1 1.57 (1.33–1.86) 1.0
Model 2 1.54 (1.28–1.85) 1.0
Model 3 1.52 (1.24–1.87) 1.0
Per 1-SD
Increase (22.8)
Range (mg/dl) 0.
Cases 143
Model 1 1.29 (1.09–1.52) 1.0
Model 2 1.27 (1.05–1.53) 1.0
Model 3 1.24 (1.00–1.53) 1.0
P
Model 3 1.36 (1.18–1.57) 1.0
Values are relative risk (95% CI) unless otherwise indicated. Model 1:
fasting status, and smoking). Model 2: adjusted for matching factors, t
factors, triglycerides, HDL-C, LDL-C, hsCRP, HbA1c, parental history
hypertension, diabetes, hypercholesterolemia, BMI, aspirin use, and p
Lp(a)  lipoprotein (a); other abbreviations as in Table 1.
Relative Risks and 95% CIs for Peripheral Artery Disease AccordinTable 4 Relative Risks and 95% CIs for Peripheral Artery Disea
IgG AA
W
Per 1-SD
Increase
log(IgG AA)
Tertile
1 2 3
Range
(RLU)
1,465–6,580 6,581–11,017 11,018–57,009
Cases 144 40 56 48
Model 1 1.16 (0.96–1.40) 1.0 (ref) 1.53 (0.95–2.45) 1.26 (0.78–2.02
Model 2 1.16 (0.95–1.42) 1.0 (ref) 1.48 (0.89–2.46) 1.32 (0.80–2.17
Model 3 1.10 (0.88–1.37) 1.0 (ref) 1.42 (0.79–2.53) 1.13 (0.65–1.96
Per 1-SD
Increase
log(IgG AA)
Tertile
1 2 3
Range
(RLU)
485–1,940 1,941–3,690 3,691–64,956
Cases 143 57 40 46
Model 1 0.94 (0.79–1.12) 1.0 (ref) 0.57 (0.35–0.93) 0.73 (0.46–1.15
Model 2 0.87 (0.71–1.06) 1.0 (ref) 0.52 (0.30–0.89) 0.54 (0.32–0.92
Model 3 0.84 (0.67–1.06) 1.0 (ref) 0.58 (0.31–1.08) 0.52 (0.29–0.95
Values are relative risk (95% CI) unless otherwise indicated. Model 1: adjusted for matching facto
for matching factors, triglycerides, HDL-C, LDL-C, hsCRP, and HbA1c. Model 3: adjusted for matc
pack-years of smoking, physical activity, hypertension, diabetes, hypercholesterolemia, BMI, aspirin use,
Abbreviations as in Table 1.0.761 with the addition of OxPL/apoB and Lp(a),
respectively, to a list of traditional risk factors (Table 6).
These risk factors include age, race (women only), month
of blood draw, fasting status, smoking status, parental
history of MI before age 60, pack-years of smoking,
ase According to Level of Lp(a)l Artery Disease According to Level of Lp(a)
Tertile
2 3
8.5–35.0 35.1–144.6
37 72
1.04 (0.62–1.75) 2.64 (1.64–4.26)
1.11 (0.64–1.94) 2.76 (1.64–4.67)
1.37 (0.72–2.59) 2.91 (1.58–5.36)
Tertile
2 3
2.5–12.0 12.1–129.1
52 60
1.88 (1.13–3.13) 2.51 (1.49–4.21)
1.27 (0.73–2.22) 1.91 (1.08–3.39)
1.20 (0.64–2.25) 1.59 (0.84–3.00)
1.28 (0.82–2.00) 2.18 (1.40–3.39)
d for matching factors (age, race [women only], month of blood draw,
ides, HDL-C, LDL-C, hsCRP, and HbA1c. Model 3: adjusted for matching
before 60 years of age, pack-years of smoking, physical activity,
nopausal hormone use (women only).
evel of AA to MDA-LDLccording to Level of AA to MDA-LDL
IgM AA
Per 1-SD
Increase
Tertile
1 2 3
nge
(RLU)
2,013–15,741 15,742–22,494 22,495–77,968
es 144 50 34 60
del 1 1.13 (0.95–1.36) 1.0 (ref) 0.59 (0.35–0.98) 1.34 (0.84–2.13)
del 2 1.10 (0.91–1.34) 1.0 (ref) 0.57 (0.34–0.97) 1.32 (0.81–2.17)
del 3 1.00 (0.80–1.26) 1.0 (ref) 0.47 (0.26–0.85) 1.05 (0.60–1.85)
Per 1-SD
Increase
Tertile
1 2 3
nge
(RLU)
732–7,203 7,204–11,833 11,834–94,623
es 143 45 44 54
del 1 1.13 (0.96–1.34) 1.0 (ref) 0.91 (0.56–1.49) 1.25 (0.80–1.97)
del 2 1.18 (0.97–1.43) 1.0 (ref) 0.83 (0.48–1.43) 1.17 (0.70–1.96)
del 3 1.13 (0.93–1.39) 1.0 (ref) 1.02 (0.55–1.87) 1.26 (0.71–2.23)
race [women only], month of blood draw, fasting status, and smoking status). Model 2: adjusted
ctors, triglycerides, HDL-C, LDL-C, hsCRP, HbA1c, parental history of MI before 60 years of age,y Diseiphera
omen
1
1–8.4
35
(ref)
(ref)
(ref)
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(ref)
(ref)
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olemia, BMI, aspirin use, and post-menopausal hormone
use (women only). In men, the improvement was smaller:
0.728 to 0.731 and 0.735 with the addition of OxPL/
apoB and Lp(a), respectively. Comparing OxPL/apoB
and Lp(a) with other standard biomarkers, the magnitude
of association between a 1-SD increase in OxPL/apoB
and Lp(a) and risk of PAD was similar to that for LDL
cholesterol and high-density lipoprotein cholesterol in
men (Fig. 4).
Relative Risks and 95% CIs for Peripheral Artery Disease AccordinTable 5 Relative Risks and 95% CIs for Peripheral Artery Disea
IgG ApoB-IC
W
Per 1-SD
Increase
Tertile
1 2 3
Range
(RLU)
272–906 907–1,328 1,329–12,372
Cases 144 41 58 45
Model 1 1.00 (0.82–1.21) 1.0 (ref) 1.53 (0.96–2.44) 1.15 (0.71–1.88
Model 2 0.97 (0.78–1.20) 1.0 (ref) 1.55 (0.94–2.55) 1.08 (0.64–1.83
Model 3 0.96 (0.73–1.24) 1.0 (ref) 1.67 (0.96–2.93) 0.94 (0.51–1.74
Per 1-SD
Increase
Tertile
1 2 3
Range
(RLU)
459–
1,460
1,461–2,061 2,062–28,725
Cases 143 54 43 46
Model 1 0.88 (0.68–1.13) 1.0 (ref) 0.68 (0.43–1.08) 0.77 (0.48–1.24
Model 2 0.89 (0.68–1.15) 1.0 (ref) 0.65 (0.38–1.09) 0.84 (0.49–1.44
Model 3 0.86 (0.63–1.17) 1.0 (ref) 0.65 (0.36–1.19) 0.98 (0.53–1.82
Values are n (range) unless otherwise indicated. Model 1: adjusted for matching factors (age, race
factors, triglycerides, HDL-C, LDL-C, hsCRP, and HbA1c. Model 3: adjusted for matching factors, t
hysical activity, hypertension, diabetes, hypercholesterolemia, BMI, aspirin use and post-menopa
IC  immune complexes; other abbreviations as in Table 1.
C-Statistic Values for Area Under theReceiver-Operating Cha acteristic CurvesTable 6 C-Statistic V lues for Area Under theReceiver-Operating Characteristic Curves
Women Men
Traditional risk factors 0.725 0.728
Traditional risk factors  OxPL/apoB 0.756 0.731
Traditional risk factors  Lp(a) 0.761 0.735
Traditional risk factors  triglycerides 0.727 0.741
Traditional risk factors  HDL-C 0.726 0.761
Traditional risk factors  LDL-C 0.727 0.734
Traditional risk factors, OxPL/apoB, Lp(a) 0.759 0.736
Traditional risk factors, OxPL/apoB, Lp(a), triglycerides 0.762 0.749
Traditional risk factors, OxPL/apoB, Lp(a),
triglycerides, HDL-C
0.763 0.769
Traditional risk factors, OxPL/apoB, Lp(a),
triglycerides, HDL-C, LDL-C
0.763 0.780
Traditional risk factors: matching factors (age, race [women only], month of blood draw, fasting
status, and smoking status), parental history of MI before 60 years of age, pack-years of smoking,
physical activity, hypertension, diabetes, hypercholesterolemia, BMI, aspirin use, and post-
menopausal hormone use (women only).
Abbreviations as in Table 1.Discussion
This study demonstrates that OxPL/apoB levels are posi-
tively associated with risk of PAD in men and women, with
no appreciable attenuation after adjustment for conventional
risk factors. Risk of developing PAD was approximately
doubled among those in the highest compared with the
lowest tertile. The Lp(a), the main lipoprotein carrier of
OxPL, was similarly associated with risk of PAD. By
contrast, we found no consistent relationship of indirect
measures of oxidized lipoproteins such as autoantibodies to
MDA-LDL and apoB-immune complexes with risk of
PAD.
The role of OxPL and the role of the innate and adaptive
immune system in mediating many pro-atherogenic pro-
cesses is well-established in experimental models (10,11,23).
However, clinical evidence is limited due to the absence of
adequate diagnostic and therapeutic tools to measure ath-
erosclerosis. In particular, biomarkers to predict PAD have
been lacking (24). The OxPL/apoB is a validated biomarker
that reflects anatomical coronary, carotid and femoral artery
disease, atherosclerosis, and predicts 15-year risk of myo-
cardial infarction and stroke (7) and allows re-classification of
almost one-third of patients in the intermediate Framingham
risk category to either lower- or high-risk categories (25).
In this study, we demonstrate the novel observation that
elevated levels of OxPL/apoB are associated with PAD in
both men and women in nested case-control studies within
2, well-validated epidemiological cohorts. The odds ratios
evel of ICccording to Level of IC
IgM ApoB-IC
Per 1-SD
Increase
Tertile
1 2 3
nge
(RLU)
23–1,142 1,143–2,050 2,051–21,500
ses 144 49 52 53
odel 1 1.13 (0.95–1.33) 1.0 (ref) 0.78 (0.48–1.26) 1.13 (0.71–1.80)
odel 2 1.15 (0.96–1.38) 1.0 (ref) 0.82 (0.49–1.38) 1.21 (0.74–1.98)
odel 3 1.14 (0.92–1.41) 1.0 (ref) 0.78 (0.45–1.37) 1.08 (0.61–1.91)
Per 1-SD
Increase
Tertile
1 2 3
nge
(RLU)
96–685 686–1,235 1,236–59,411
ses 143 49 47 47
odel 1 1.08 (0.97–1.21) 1.0 (ref) 0.90 (0.57–1.43) 0.94 (0.60–1.48)
odel 2 1.10 (0.93–1.31) 1.0 (ref) 0.90 (0.54–1.52) 0.97 (0.59–1.59)
odel 3 1.13 (0.91–1.42) 1.0 (ref) 1.11 (0.63–1.97) 0.97 (0.55–1.73)
n only], month of blood draw, fasting status, and smoking status). Model 2: adjusted for matching
ides, HDL-C, LDL-C, hsCRP, HbA1c, parental history of MI before age 60, pack-years of smoking,
rmone use (women only).g to Lse A
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Interestingly, in women, the curve was shifted to the left
compared with men, suggesting a stronger association with
lower OxPL/apoB values. Furthermore, the OxPL/apoB
relationship to PAD was different than the Lp(a) relation-
ship in women, with a similar left shift. This might reflect
differences in OxPL content among Lp(a) particles, with
higher OxPL in Lp(a) associated with small isoforms (28).
This hypothesis-generating observation needs to be repli-
cated, but it does suggest OxPL/apoB might be particularly
useful in women. Our finding that an easily measured
marker of lipid oxidation is independently associated with
risk of PAD also provides evidence that oxidative stress
might indeed be an important contributor to atherosclerosis
and provides a potentially useful tool to test this hypothesis
in future studies.
We likewise found a positive association between Lp(a)
and risk of PAD, an area where previous studies have been
discordant. Some (29–36), but not all (30,37–39), cross-
sectional studies tend to show positive associations between
Lp(a) and PAD or PAD progression, and 1 longitudinal
study found a positive association (36). In contrast to PAD,
data on the role of Lp(a) in the development of CVD is
fairly consistent for a modest, independent association (40).
A recent pooled analysis found that the RRs of CHD and
ischemic stroke/1-SD increase in Lp(a) were 1.13 (95% CI:
1.09 to 1.18) and 1.10 (95% CI: 0.97 to 1.04), respectively,
after adjusting for lipids and other conventional risk factors
Figure 4 Adjusted Relationship Between Oxidation-Specific and
Adjusted for age, race (women only), fasting status, smoking, triglycerides, high-de
high-sensitivity C-reactive protein, hemoglobin A1c (HbA1c), parental history of myoc
diabetes, hypercholesterolemia, body mass index, aspirin use, and post-menopau
AA  autoantibodies; IC  immune complexes; Ig  immunoglobulin; other abb(41). We observed a pooled RR of PAD/1-SD that was emore than twice as strong as the previous estimate for CHD
(estimated ln[RR] of 0.12 vs. 0.31), suggesting that Lp(a)
might be a stronger risk factor for PAD than for other forms
of CVD; however, more studies are needed to confirm this
observation definitively.
Despite a recent focus on OxPL and Lp(a) as cardiovas-
cular disease risk factors, the etiologic link between Lp(a)
and atherosclerosis remains unclear. Lp(a) mediates athero-
genesis through mechanisms linked to its LDL and apo(a)
components and its associated pro-inflammatory OxPL
(42). A link was recently established between OxPL and
Lp(a) in mediating macrophage apoptosis, a common
mechanism for plaque progression and destabilization (43).
Given that atherosclerosis represents a dynamic process
f lipid deposition and reverse transport, clearance of
xidized particles would be anticipated to prevent athero-
clerotic progression. In this study, we measured autoanti-
odies to MDA-LDL, which would be anticipated to serve
s a sink for circulating oxidized LDL particles. Some, but
ot all (44), previous studies found an inverse association
etween levels of IgM autoantibodies to MDA-LDL and
ardiovascular disease, including coronary artery disease
45), hypertension (46), MI (47–49), and carotid and
emoral atherosclerosis (14,15). It is interesting that we
ound an inverse relationship between IgG to MDA-LDL
nd risk of PAD in men but not in women. With this
xception, we found no other consistent associations of
ndard Biomarkers and RR of PAD
ipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C),
infarction before age 60, pack-years of smoking, physical activity, hypertension,
rmone use (women only).
ons as in Figure 1.Sta
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Oxidation Biomarkers and Peripheral Artery Disease May 28, 2013:2169–79Strengths of our study include adjudicated cases of
clinically meaningful PAD in both sexes, the high quality
measurement of both biochemical and behavioral confound-
ers, and the use of risk set sampling to select control
subjects, which minimizes bias due to control subjects not
accurately reflecting the source population from which the
cases came. In addition, this is the first study to our
knowledge that prospectively examines the association be-
tween novel cardiovascular risk factors OxPL/apoB, auto-
antibodies, and IC and risk of PAD.
Study limitations. Our study is not without limitation.
here is a possibility of unmeasured or residual confound-
ng, and because the NHS and HPFS studies contain
redominantly white participants, we cannot necessarily
eneralize to minority populations, some of whom are at
ncreased risk for PAD. However, we have no evidence that
xidative stress is less important in these populations, and
ndeed, recent evidence suggests that Lp(a) is strongly
ssociated with CHD and ischemic stroke in both blacks
nd whites (50).
A potential limitation of studies of clinically significant
AD like this one is the possibility that some control
ubjects have undiagnosed PAD. Although this is a poten-
ial weakness of all studies of CVD events (e.g., individuals
ree of MI might nonetheless have asymptomatic coronary
therosclerosis), our results might be a conservative estimate
f the association between OxPL/apoB and risk of PAD if
ontrol subjects have unrecognized PAD. However, all
tudy participants are health professionals who report al-
ost universal access to health care, which would tend to
inimize undiagnosed cases. Regardless, our endpoint re-
ects clinically significant and meaningful cases of greatest
oncern to both patients and physicians. Finally, our results
lone cannot definitively separate OxPL and Lp(a) as
ndividual determinants of PAD, given their inherent bio-
ogical interrelationship.
onclusions
xPL/apoB are positively associated with risk of PAD and
re a unique oxidation-specific biomarker that it is not
ssociated with other traditional CVD risk factors besides
p(a), the major lipoprotein carrier of OxPL. Future
esearch should continue to explore the mechanisms that
ink oxidation to risk of PAD and test whether modifiable
isk factors, potentially including novel therapies that reduce
evels of OxPL, might prevent the development of athero-
clerotic diseases such as PAD.
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